There is good news for people with diabetes. The study, published in the Journal of Clinical Investigation, reveals the presence of drugs that stop the development of type 1 diabetes

After examining thousands of drugs through super-sophisticated computers, it was revealed that the drug methyldopa that has been used to treat hypertension in pregnant women was able to block the D08 molecule.

Although not yet able to guarantee 100 percent can cure, at least, this drug works to block the development of the onset of type 1 diabetes. Moreover, this diabetes can strike children from an early age.

Type 1 diabetes disrupts the human immunity. The pancreas fails to regulate insulin production, insulin is not produced or can not be used effectively. Absorption of glucose and energy is impaired when a person has type 1 diabetes.

read also new connection found between nicotine and type 2 diabetes

This 10-year-old study not only takes advantage of computer sophistication. Rats and humans are also involved as drug samples. A total of 20 individuals with diabetes risk factors were asked to swallow the drug three times a day.

After that the effect is monitored. Researchers say, the drug is capable of triggering immunity in 60 percent of individuals with diabetes risk factors. Another advantage of this drug is not to weaken the immunity of other cells.

“This is a personal treatment for the first time, which prevents type 1 diabetes,” says Aaron Michels, a University of Colorado researcher.

“Hopefully, this drug can delay or prevent the occurrence of disease among those at risk,” he added.

This study also opens the opportunity to cure other autoimmune diseases. Drug analysis methods with modern computational systems can be replicated and applied to find out the effectiveness of the drug.

read also new study may lead to improved treatment of type 2 diabetes

“The same approach can be adapted to prevent autoimmune diseases such as rheumatoid arthritis, colic disease, multiple sclerosis, systemic lupus erythematosus, and so on,” says David Ostrov, a researcher at the University of Florida.


Please enter your comment!
Please enter your name here